FDA Clears Aredia for Use in Treating Bone Metastases of Breast Cancer
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia (pamidronate disodium for injection) for the treatment of patients with osteolytic bone metastases of breast cancer, in conjunction with standard antineoplastic therapy.
ROCKVILLE, Md--The FDA has cleared Chiron Therapeutics' Aredia(pamidronate disodium for injection) for the treatment of patientswith osteolytic bone metastases of breast cancer, in conjunctionwith standard antineoplastic therapy.
The drug has been on the market since 1991 and is also indicatedfor the treatment of osteolytic bone lesions of multiple myeloma,moderate-to-severe hypercalcemia of malignancy, and moderate-to-severePaget's disease.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
